Illumina Inc. Common Stock (ILMN)
Stock · NASDAQ · Health Care
$262.52as of 10/16/2026
Price chart
Active signals
ILMN Signal Track Record
How signals performed across all stocks →What ILMN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | +0.6% | 53% | September 2, 2026 |
| Bollinger Band Breakout | 24 | +3.3% | 67% | September 17, 2026 |
| Bollinger Band Breakdown | 21 | -0.4% | 48% | April 29, 2026 |
| 200-Day Moving Average TouchActive now | 14 | +0.3% | 50% | October 16, 2025 |
| Any 20-session window (baseline) | +1.1% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ILMN
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targe…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 8,600
- Website
- www.illumina.com
Fundamentals
- 1-day range
- $257.14$275.47
- Market cap
- $29.25B
- P/E (trailing)
- 48.62
- P/E (forward)
- 43.79
- EPS (trailing)
- $5.38
- Dividend yield
- —
- Beta
- 1.43
- Avg. volume
- 2.74M
How Illumina Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
20 analyst ratings
Illumina Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ILMNIllumina Inc. Common Stock$262.54▼ 2.01%Market cap $29.25BP/E 48.62$88$309.35
- CNCCentene Corporation Common Stock$69.16▼ 1.91%Market cap $31.71BP/E —$31.63$70.37
- DGXQuest Diagnostics Incorporated Common Stock$235▼ 1.74%Market cap $26.32BP/E 24.67$171.18$248.84
- LHLabcorp Holdings Inc. Common Stock$317.95▼ 2.19%Market cap $25.96BP/E 25.55$244.52$341.8
- GHGuardant Health Inc. Common Stock$158.6▼ 4.39%Market cap $21.15BP/E —$61$191.05
- NTRANatera Inc. Common Stock$393.44▼ 2.80%Market cap $38.01BP/E —$170.82$437.41
- HUMHumana Inc. Common Stock$413.16▼ 4.41%Market cap $44.10BP/E 39.25$163.11$456.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ILMN Illumina Inc. Common Stock | $29.25B | 48.62 | $262.54 | ▼ 2.01% | $88$309.35 |
| CNC Centene Corporation Common Stock | $31.71B | — | $69.16 | ▼ 1.91% | $31.63$70.37 |
| DGX Quest Diagnostics Incorporated Common Stock | $26.32B | 24.67 | $235 | ▼ 1.74% | $171.18$248.84 |
| LH Labcorp Holdings Inc. Common Stock | $25.96B | 25.55 | $317.95 | ▼ 2.19% | $244.52$341.8 |
| GH Guardant Health Inc. Common Stock | $21.15B | — | $158.6 | ▼ 4.39% | $61$191.05 |
| NTRA Natera Inc. Common Stock | $38.01B | — | $393.44 | ▼ 2.80% | $170.82$437.41 |
| HUM Humana Inc. Common Stock | $44.10B | 39.25 | $413.16 | ▼ 4.41% | $163.11$456.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- $100 Invested In Illumina 15 Years Ago Would Be Worth This Much Todaybenzinga · 10/14/2026
- Could You Have Seen The Run In Tempus AI Stock Coming?Yahoo · 10/9/2026
- What is Illumina’s (ILMN) Economic Moat, and is it Widening or Narrowing?Yahoo · 10/9/2026
- Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026Yahoo · 10/8/2026
- Which S&P500 stocks are gapping on Thursday?ChartMill · 10/8/2026
- Illumina releases SpliceAI2 to help advance rare disease researchYahoo · 10/8/2026
- Barclays Maintains Underweight on Illumina, Raises Price Target to $200Benzinga · 10/7/2026
- Stocks making big moves yesterday: Harley-Davidson, Illumina, TechnipFMC, Upstart, and DraftKingsYahoo · 10/6/2026
- Uncover the latest developments among S&P500 stocks in today's session.ChartMill · 10/6/2026
Insider Activity
Insider Actions →- Jacob Thaysen · October 5, 2026 · Tax Withholding1.3K @ $293.69
- Keith A. Meister · September 30, 2026 · Grant107 @ $219.8
- Scott B. Ullem · September 30, 2026 · Grant113 @ $219.8
- Julie Ann Coletti · September 8, 2026 · Grant5.3K
- Julie Ann Coletti · September 8, 2026 · Grant14.2K
- Julie Ann Coletti · September 8, 2026 · Grant4.5K
- Steven Barnard · September 5, 2026 · Tax Withholding408 @ $211.06
- Keith A. Meister · September 4, 2026 · Sale11.4K @ $219.18
- Keith A. Meister · September 4, 2026 · Sale100.7K @ $218.39
- Keith A. Meister · September 4, 2026 · Sale7.5K @ $217.28
- Keith A. Meister · September 3, 2026 · Sale10.0K @ $221.55
- Keith A. Meister · September 3, 2026 · Sale6.7K @ $220.17
- Keith A. Meister · September 3, 2026 · Sale13.7K @ $219.41
- Keith A. Meister · September 3, 2026 · Sale9.7K @ $218.33
- Keith A. Meister · September 3, 2026 · Sale14.2K @ $217.29
Institutional Ownership
March 31, 2026
- Total shares held
- 147.77M
- Total value held
- $17.72B
- Institutional holders
- 834
- Unknown19.02M
- Unknown15.55M
- Unknown6.59M
- Unknown6.43M
- Unknown5.92M
- Unknown3.98M
- Unknown3.83M
- Unknown3.28M
- Unknown3.05M
- Unknown2.94M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends
Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.